Role of progestins with partial antiandrogenic effects

References

• Writing Group for the Women's Health In-itiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmeno-pausal women: Principal results from the Women's Health Initiative randomized con-trolled trial. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expecta-tions shape experience? Ann Intern Med 2003;139:923–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Post-menopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. a prospective, observational study. Ann Intern Med 2001;135:1–8
   Google Scholar
• Burger HG. Androgen production in women. Fertil Steril 2002;77(Suppl 4):S3–S5
   PubMed Web of Science ®Google Scholar
• Longcope C, Hunter R, Franz C. Steroid secretion by the postmenopausal ovary. Am J Obstet Gynecol 1980;138:564–8
   Google Scholar
• Honore LH, Chari R, Mueller HD, et al. Postmenopausal hyperandrogenism of ovarian origin, a clinicopathologic study of four cases. Gynecol Obstet Invest 1992;34:52–6
   PubMed Web of Science ®Google Scholar
• Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341–55
   Google Scholar
• Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404–11
   PubMed Web of Science ®Google Scholar
• Hajamor S, Despres JP, Couillard C, et al. Relationship between sex hormone-binding globulin levels and features of the metabolic syndrome. Metabolism 2003;52:724–30
   PubMed Web of Science ®Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188–215
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Small M. New methods of progestin delivery. Contem Clin Gynecol Ob-stet 2002;2:287–98
   Google Scholar
• Schneider HP. The role of antiandrogens in hormone replacement therapy. Climacteric 2000;3(Suppl 2):21–7
   PubMedGoogle Scholar
• Krattenmacher R. Drospirenone: pharmacol-ogy and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38
   PubMed Web of Science ®Google Scholar
• Oettel M, Graser T, Hoffman H, et al. Why dienogest as a progestogenic component of postmenopausal nonadrenergic hormone re-placement therapy? Drugs Today 2001;37:3–15
   Web of Science ®Google Scholar
• Schindler AE. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. Eur J Obstet Gynecol Reprod Biol 2004;112:136–41
   PubMed Web of Science ®Google Scholar
• Duc I, Botella J, Bonnet P, et al. Antiandrogenic properties of nomegestrol acetate. Arzneimit-telforschung 1995;45:70–4
   PubMed Web of Science ®Google Scholar
• Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915–20
   Google Scholar
• Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci 2003;997:292–306
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65:629–36
   PubMed Web of Science ®Google Scholar
• Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpreg-nance progestin (trimegestone). Gynecol Endocrinol 1999;13:316–26
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6–15
   PubMed Web of Science ®Google Scholar
• Graser T, Koytchev R, Muller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest com-binations and Kliogest for continuous combined hormone replacement therapy in postmenopau-sal women. Climacteric 2000;3:109–18
   PubMedGoogle Scholar
• Graser T, Romer T, Wiedey KD, et al. Climodien (estradiol valerate 2 mg plus dieno-gest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001;4:332–42
   PubMedGoogle Scholar
• Rabig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and anti-androgenic properties. Climacteric 2003; 6(Suppl):49–54
   Google Scholar
• Al Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone re-placement therapy: a dose-ranging study. Hum Reprod 1999;14:636–41
   PubMed Web of Science ®Google Scholar
• Al Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential com-binations of trimegestone or norethisterone acetate. Climacteric 2001;4:343–54
   PubMedGoogle Scholar
• Grubb G, Spielmann D, Pickar J, et al. Clinical experience with trimegestone as a new proges-tin in HRT. Steroids 2003;68:921–6
   PubMed Web of Science ®Google Scholar
• Wahab M, Thompson J, Whitehead M, et al. The effect of a change in the dose of trimeges-tone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study. Hum Re-prod 2002;17:1386–90
   Google Scholar
• Sidelmann JJ, Jespersen J, Andersen LF, et al. Hormone replacement therapy and hypercoa-gulability. Results from the Prospective Collaborative Danish Climacteric Study. Br J Obstet Gynaecol 2003;110:541–7
   Google Scholar
• Andersen LF, Gram J, Skouby SO, et al. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 1999;180:283–9
   PubMed Web of Science ®Google Scholar
• Skouby SO, Gram J, Andersen LF, et al. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969–77
   PubMed Web of Science ®Google Scholar
• Friend KE, Hartman ML, Pezzoli SS, et al. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 1996;81:2250–6
   PubMed Web of Science ®Google Scholar
• Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51–8
   PubMed Web of Science ®Google Scholar
• Akhrass F, Evans AT, Wang Y, et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2003; 88:5611–4
   PubMed Web of Science ®Google Scholar
• Weissberger AJ, Ho KK, Lazarus L. Contrast-ing effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72: 374–81
   Google Scholar
• Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68:183–223
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Biglia N, Lanza MG, et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postme-nopausal women. Preliminary report. Maturitas 1994;19:25–31
   PubMed Web of Science ®Google Scholar
• Span JP, Pieters GF, Sweep CG, et al. Gender difference in insulin-like growth factor I re-sponse to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 2000;85:1121–5
   PubMed Web of Science ®Google Scholar
• Isaksson E, Sahlin L, Soderqvist G, et al. Expression of sex steroid receptors and IGF-1 mRNA in breast tissue - effects of hormonal treatment. J Steroid Biochem Mol Biol 1999;70:257–62
   PubMed Web of Science ®Google Scholar
• Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 2003;10:331–45
   PubMed Web of Science ®Google Scholar
• Hamelers IHL, van Schiak RFMA, van Teffelen HA, et al. IGF-1 action is essential for estrogen stimulated growth of MCF-7 breast tumor cells. Presented at the Denver, CO, June 2001;PI–193
   Google Scholar
• Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–6
   PubMed Web of Science ®Google Scholar
• Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prey 1995; 4:567–71
   PubMed Web of Science ®Google Scholar
• Catalano MG, Comba A, Fazzari A, et al. Sex steroid binding protein receptor (SBP-R) is related to a reduced proliferation rate in human breast cancer. Breast Cancer Res Treat 1997;42:227–34
   PubMed Web of Science ®Google Scholar
• Fazzari A, Catalano MG, Comba A, et al. The control of progesterone receptor expression in MCF-7 breast cancer cells: effects of estradiol and sex hormone-binding globulin (SHBG). Mol Cell Endocrinol 2001;172:31–6
   PubMed Web of Science ®Google Scholar
• Elizalde PV, Lanari C, Molinolo AA, et al. Involvement of insulin-like growth factors-I and -II and their receptors in medroxyproges-terone acetate-induced growth of mouse mammary adenocarcinomas. J Steroid Biochem Mol Biol 1998;67:305–17
   PubMed Web of Science ®Google Scholar
• Cline JM, Soderqvist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93–100
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial prolifera-tion in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559–65
   PubMed Web of Science ®Google Scholar
• Hargreaves DF, Knox F, Swindell R, et al. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement ther-apy. Br J Cancer 1998;78:945–9
   PubMed Web of Science ®Google Scholar
• Dobson RR, Chan CK, Knox F, et al. The effects of prolonged HRT treatment in normal postmenopausal breast epithelium (abstract). Breast Cancer Res Treat 2000;64:106
   Google Scholar
• Stallard S, Litherland JC, Cordiner CM, et al. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. Br Med J 2000;320:348–9
   PubMed Web of Science ®Google Scholar
• Suparto IH, Williams JK, Cline JM, et al. Contrasting effects of two hormone replace-ment therapies on the cardiovascular and mammary gland outcomes in surgically post-menopausal monkeys. Am J Obstet Gynecol 2003;188:1132–40
   PubMed Web of Science ®Google Scholar
• Cline JM, Soderqvist G, von Schoultz E, et al. Effects of conjugated estrogens, medroxypro-gesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221–9
   PubMed Web of Science ®Google Scholar
• Conner P, Soderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159–65
   PubMed Web of Science ®Google Scholar
• Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al. Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol 1999;69:293–7
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Paris J, Sitruk-Ware R, et al. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998;65:225–35
   PubMedGoogle Scholar
• Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75–92
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684–9
   PubMed Web of Science ®Google Scholar
• Smith IE. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003;86:289–93
   PubMed Web of Science ®Google Scholar
• Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000;21:457–87
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Croxson MS, Ibbertson HK, et al. Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta En-docrinol (Cope* 1985;109:522–9
   PubMedGoogle Scholar
• van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2–15
   PubMedGoogle Scholar
• El-Etr M, Schumacher M. Effects of progester-one and related steroids in the brain. In Sitruk-Ware R, Mishell DRJ, eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, Inc., 2000:15–58
   Google Scholar
• Friess E, Wiedemann K, Steiger A, et al. The hypothalamic-pituitary-adrenocortical system and sleep in man. Adv Neuroimmunol 1995;5:111–25
   PubMedGoogle Scholar
• Lancel M, Cronlein TA, Muller-Preuss P, et al. Pregnenolone enhances EEG delta activity during non-rapid eye movement sleep in the rat, in contrast to midazolam. Brain Res 1994;646:85–94
   Google Scholar
• Majewska MD, Bluet-Pajot MT, Robel P, et al. Pregnenolone sulfate antagonizes barbiturate-induced hypnosis. Pharmacol Biochem Behav 1989;33: 701–3
   PubMed Web of Science ®Google Scholar
• Steiger A, Trachsel L, Guldner J, et al. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse ago-nistic GABAA_receptor modulation. Brain Res 1993;615:267–74
   PubMed Web of Science ®Google Scholar
• Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-preg-nan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991;561: 157–61
   Google Scholar
• Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171–7
   Google Scholar
• Eriksson H, Haasio J, Korttila K. Comparison of eltanolone and thiopental in anaesthesia for termination of pregnancy. Acta Anaesthesiol Scand 1995;39:479–84
   PubMedGoogle Scholar
• Brot MD, Akwa Y, Purdy RH, et al. The anxiolytic-like effects of the neurosteroid allo-pregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 1997;325:1–7
   PubMed Web of Science ®Google Scholar
• Patchev VK, Shoaib M, Holsboer F, et al. The neurosteroid tetrahydroprogesterone counter-acts corticotropin-releasing hormone-induced anxiety and alters the release and gene expres-sion of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 1994;62:265–71
   PubMed Web of Science ®Google Scholar
• Patchev VK, Hassan AH, Holsboer DF, et al. The neurosteroid tetrahydroprogesterone at-tenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 1996;15:533–40
   PubMed Web of Science ®Google Scholar
• Shifren JL. Androgen deficiency in the oophor-ectomized woman. Fertil Steril 2002;77(Suppl 4):S60–S62
   PubMedGoogle Scholar
• Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophor-ectomy. N Engl J Med 2000;343:682–8
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopau-sal transition. Fertil Steril 2002;77(Suppl 4):S42–S48
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Gotts G, Brown JB, et al. The relationship between the menstrual cycle and female sexual interest in women with PMS complaints and volunteers. Psychoneuroendo-crinology 1994;19:293–304
   PubMed Web of Science ®Google Scholar
• Frye CA. The role of neurosteroids and non-genomic effects of progestins in the ventral tegmental area in mediating sexual receptivity of rodents. Horm Behav 2001;40:226–33
   PubMed Web of Science ®Google Scholar
• McEwen BS. Genomic regulation of sexual behavior. J Steroid Biochem 1988;30:179–83
   PubMedGoogle Scholar
• Sinchak K, Micevych PE. Progesterone block-ade of estrogen activation of mu-opioid receptors regulates reproductive behavior. J Neurosci 2001;21:5723–9
   PubMed Web of Science ®Google Scholar
• Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162–70
   PubMed Web of Science ®Google Scholar
• Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal admin-istration of opioids. J Clin Endocrinol Metab 2000;85:2215–22
   PubMed Web of Science ®Google Scholar
• Stomati M, Bersi C, Rubino S, et al. Neuroen-docrine effects of different estradiol-progestin regimens in postmenopausal women. Maturitas 1997;28:127–35
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Trentini GP, Petraglia F, et al. Estrogens modulate the circadian rhythm of hypothalamic beta-endorphin contents in fe-male rats. Neuroendocrinology 1990;52:221–4
   PubMed Web of Science ®Google Scholar
• Davis SR, McCloud P, Strauss BJ, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227–36
   PubMed Web of Science ®Google Scholar
• Sherwin BB. Randomized clinical trials of combined estrogen-androgen preparations: ef-fects on sexual functioning. Fertil Steril 2002;77:549–554
   Web of Science ®Google Scholar
• Kokcu A, Cetinkaya MB, Yanik F, et al. The comparison of effects of tibolone and conju-gated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmeno-pausal women. Maturitas 2000;36:75–80
   PubMed Web of Science ®Google Scholar
• Albertazzi P, Natale V, Barbolini C, et al. The effect of tibolone versus continuous combined norethisterone acetate and oestradiol on mem-ory, libido and mood of postmenopausal women: a pilot study. Maturitas 2000;36: 223–9
   PubMed Web of Science ®Google Scholar
• Raudrant D, Rabe T. Progestogens with anti-androgenic properties. Drugs 2003;63:463–92
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Dietrich H, Wisser KH, et al. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Con-tracept Reprod Health Care 1999;4:155–64
   PubMed Web of Science ®Google Scholar
• Anderer P, Semlitsch HV, Saletu B, et al. Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in meno-pausal insomnia. Psychoneuroendocrinology 2003;28:419–45
   PubMed Web of Science ®Google Scholar
• Saletu B, Anderer P, Gruber D, et al. Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients. Maturitas 2002;43:165–81
   PubMed Web of Science ®Google Scholar
• Saletu B. Ostrogene und Vigilanz älterer Frauen, objectiviert mittes EEG-Mapping. In Lauritzen C, ed. Altersgynäkologie: Stuttgart: Georg Thieme Verlag, 1997:163–73
   Google Scholar
• Saletu B. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. Climacteric 2003; 6(Suppl):37–45
   Google Scholar
• Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 2001;57: 2210–6
   PubMed Web of Science ®Google Scholar
• Smith YR, Giordani B, Lajiness-O'Neill R, et al. Long-term estrogen replacement is asso-ciated with improved nonverbal memory and attentional measures in postmenopausal wo-men. Fertil Steril 2001;76:1101–7
   Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized con-trolled trial. J Am Med Assoc 2003;289:2651–62
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Wisser KH, Dietrich H. The effects of Valette on skin and hair: a post-marketing surveillance study. Int J Clin Pract 2000;54:85–91
   Google Scholar
• Mueck AO, Seeger H, Ludtke R, et al. Effect on biochemical vasoactive markers during post-menopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas 2001;38:305–13
   PubMed Web of Science ®Google Scholar
• Gräser T, Koytchev R, Georgiev DB, et al. Dienogest as a progestin for hormone replace-ment therapy. Drugs Today 1999;35:115–26
   Google Scholar
• Gaspard U. Pharma-clinics. Medication of the month. Totelle Cycle: new sequential estrogen/ progesterone regimen for hormone replacement therapy in menopause. Rev Med Liege 2002;57:408–12
   Google Scholar
• Wahab M, Al Azzawi F. Trimegestone: ex-panding therapeutic choices for the treatment of the menopause. Expert Opin Invest Drugs 2001;10:1737–44
   PubMed Web of Science ®Google Scholar
• Meuwissen JH, Beijers-De Bie L, Vihta-maki T, et al. A 1-year comparison of the efficacy and clinical tolerance in post-menopausal women of two hormone replace-ment therapies containing estradiol in combination with either norgestrel or trimegestone . Gynecol Endocrinol 2001; 15:349–58
   PubMed Web of Science ®Google Scholar
• Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891–905
   PubMed Web of Science ®Google Scholar